Submission |
Feb. 27, 2025 |
|---|---|
| Submission [Line Items] | |
| Central Index Key | 0001658247 |
| Registrant Name | Crinetics Pharmaceuticals, Inc. |
| Form Type | S-8 |
| Submission Type | S-8 |
| Fee Exhibit Type | EX-FILING FEES |
Offerings |
Feb. 27, 2025
USD ($)
shares
|
|---|---|
| Offering: 1 | |
| Offering: | |
| Fee Previously Paid | false |
| Other Rule | true |
| Security Type | Equity |
| Security Class Title | Common stock, $0.001 par value |
| Amount Registered | shares | 4,646,320 |
| Proposed Maximum Offering Price per Unit | 37.16 |
| Maximum Aggregate Offering Price | $ 172,657,251 |
| Fee Rate | 0.01531% |
| Amount of Registration Fee | $ 26,433.83 |
| Offering Note | 1. The amount registered represents additional shares of the Registrant’s common stock that became available for issuance under the Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan (the “2018 Plan”), pursuant to the evergreen provision of the 2018 Plan. Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this Registration Statement also registers an indeterminate number of additional shares that may be issued pursuant to the 2018 Plan as a result of any future stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. The proposed maximum offering price per share and proposed maximum aggregate offering price for the shares of the common stock covered by this Registration Statement have been estimated in accordance with Rule 457(c) and 457(h) solely for the purpose of calculating the registration fee. The maximum price per share and the maximum aggregate offering price are based upon the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Global Select Market on February 21, 2025, which date is within five business days prior to filing this Registration Statement. |
| Offering: 2 | |
| Offering: | |
| Fee Previously Paid | false |
| Other Rule | true |
| Security Type | Equity |
| Security Class Title | Common stock, $0.001 par value |
| Amount Registered | shares | 929,264 |
| Proposed Maximum Offering Price per Unit | 37.16 |
| Maximum Aggregate Offering Price | $ 34,531,450 |
| Fee Rate | 0.01531% |
| Amount of Registration Fee | $ 5,286.77 |
| Offering Note | 2. The amount registered represents additional shares of the Registrant’s common stock that became available for issuance under the Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan (the “2018 ESPP”), pursuant to the evergreen provision of the 2018 ESPP. Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this Registration Statement also registers an indeterminate number of additional shares that may be issued pursuant to the 2018 ESPP as a result of any future stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. The proposed maximum offering price per share and proposed maximum aggregate offering price for the shares of the common stock covered by this Registration Statement have been estimated in accordance with Rule 457(c) and 457(h) solely for the purpose of calculating the registration fee. The maximum price per share and the maximum aggregate offering price are based upon the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Global Select Market on February 21, 2025, which date is within five business days prior to filing this Registration Statement. |
| Offering: 3 | |
| Offering: | |
| Fee Previously Paid | false |
| Other Rule | true |
| Security Type | Equity |
| Security Class Title | Common stock, $0.001 par value |
| Amount Registered | shares | 2,000,000 |
| Proposed Maximum Offering Price per Unit | 37.16 |
| Maximum Aggregate Offering Price | $ 74,320,000 |
| Fee Rate | 0.01531% |
| Amount of Registration Fee | $ 11,378.4 |
| Offering Note | 3. The amount registered represents additional shares of the Registrant’s common stock available for issuance pursuant to awards that may be granted under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “Inducement Plan”), pursuant to the fourth amendment to the Inducement Plan. Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this Registration Statement also registers an indeterminate number of additional shares that may be issued pursuant to the Inducement Plan as a result of any future stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. The proposed maximum offering price per share and proposed maximum aggregate offering price for the shares of the common stock covered by this Registration Statement have been estimated in accordance with Rule 457(c) and 457(h) solely for the purpose of calculating the registration fee. The maximum price per share and the maximum aggregate offering price are based upon the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Global Select Market on February 21, 2025, which date is within five business days prior to filing this Registration Statement. |
Fees Summary |
Feb. 27, 2025
USD ($)
|
|---|---|
| Fees Summary [Line Items] | |
| Total Offering | $ 281,508,701 |
| Total Fee Amount | 43,099 |
| Total Offset Amount | 0 |
| Net Fee | $ 43,099 |